BR112022019722A2 - N-cianopirrolidinas com atividade como inibidores de usp30 - Google Patents

N-cianopirrolidinas com atividade como inibidores de usp30

Info

Publication number
BR112022019722A2
BR112022019722A2 BR112022019722A BR112022019722A BR112022019722A2 BR 112022019722 A2 BR112022019722 A2 BR 112022019722A2 BR 112022019722 A BR112022019722 A BR 112022019722A BR 112022019722 A BR112022019722 A BR 112022019722A BR 112022019722 A2 BR112022019722 A2 BR 112022019722A2
Authority
BR
Brazil
Prior art keywords
cyanopyrrolidines
activity
usp30
inhibitors
usp30 inhibitors
Prior art date
Application number
BR112022019722A
Other languages
English (en)
Inventor
Andrew Luckhurst Christopher
Ian Kemp Mark
William Thompson Paul
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2008401.8A external-priority patent/GB202008401D0/en
Priority claimed from GBGB2016689.8A external-priority patent/GB202016689D0/en
Priority claimed from GBGB2101935.1A external-priority patent/GB202101935D0/en
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of BR112022019722A2 publication Critical patent/BR112022019722A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

N-CIANOPIRROLIDINAS COM ATIVIDADE COMO INIBIDORES DE USP30. A presente invenção refere-se a uma classe de N-cianopirrolidinas com atividade como inibidores da enzima desubiquitilante USP30, tendo utilidade em uma variedade de áreas terapêuticas, incluindo condições envolvendo disfunção mitocondrial, câncer e fibrose: (fórmula (I)(i) e (I)(ii)). .
BR112022019722A 2020-06-04 2021-06-03 N-cianopirrolidinas com atividade como inibidores de usp30 BR112022019722A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2008401.8A GB202008401D0 (en) 2020-06-04 2020-06-04 Novel compounds
GBGB2016689.8A GB202016689D0 (en) 2020-10-21 2020-10-21 Novel compounds
GBGB2101935.1A GB202101935D0 (en) 2021-02-11 2021-02-11 Novel compounds
PCT/EP2021/064897 WO2021245186A1 (en) 2020-06-04 2021-06-03 N-cyanopyrrolidines with activity as usp30 inhibitors

Publications (1)

Publication Number Publication Date
BR112022019722A2 true BR112022019722A2 (pt) 2022-12-20

Family

ID=76421953

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019722A BR112022019722A2 (pt) 2020-06-04 2021-06-03 N-cianopirrolidinas com atividade como inibidores de usp30

Country Status (12)

Country Link
US (1) US20230303547A1 (pt)
EP (1) EP4161920A1 (pt)
JP (1) JP2023529570A (pt)
KR (1) KR20230019198A (pt)
CN (1) CN115698001A (pt)
AU (1) AU2021285130A1 (pt)
BR (1) BR112022019722A2 (pt)
CA (1) CA3185654A1 (pt)
CO (1) CO2022017112A2 (pt)
IL (1) IL298710A (pt)
MX (1) MX2022015254A (pt)
WO (1) WO2021245186A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
AU2001256981A1 (en) 2000-04-06 2001-10-23 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20100022568A1 (en) 2006-04-13 2010-01-28 Actelion Pharmaceeuticals Ltd. Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
EP2152079A4 (en) 2007-06-04 2011-03-09 Avila Therapeutics Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
CL2008002430A1 (es) 2007-08-20 2009-10-16 Glaxo Group Ltd Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
AR071369A1 (es) 2008-04-18 2010-06-16 Glaxo Group Ltd Compuesto de 1- ciano-3-pirrolidinil-n-sustituido-sulfonamida, su uso para preparar un medicamento util para tratar una enfermedad pulmonar obstructiva cronica y composicion farmaceutica que lo comprende
TW201002317A (en) 2008-04-18 2010-01-16 Glaxo Group Ltd Cathepsin C inhibitors
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
US20120309820A1 (en) 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
CA2918242C (en) 2013-07-31 2022-06-21 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
WO2015179190A1 (en) 2014-05-19 2015-11-26 Northeastern University N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof
US20170095457A1 (en) 2014-05-27 2017-04-06 David Lonergan Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
AU2016240033B2 (en) 2015-03-30 2020-04-16 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as USP30 inhibitors
EP3800186A1 (en) 2015-07-14 2021-04-07 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
JP6959252B2 (ja) 2016-03-24 2021-11-02 ミッション セラピューティクス リミティド Ｄｕｂ阻害剤としての１−シアノピロリジン誘導体
EP3519385B1 (en) 2016-09-27 2020-11-18 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of usp30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
WO2018213150A1 (en) 2017-05-15 2018-11-22 Mitobridge, Inc. Usp30 inhibitors
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
GB2563595B (en) 2017-06-19 2020-04-15 Edwards Ltd Twin-shaft pumps
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
GB2571731A (en) 2018-03-06 2019-09-11 Mission Therapeutics Ltd Novel compounds and uses
MX2020012180A (es) 2018-05-17 2021-01-29 Forma Therapeutics Inc Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina.
JP7434285B2 (ja) 2018-08-14 2024-02-20 アムジエン・インコーポレーテツド Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用
EP3860989B1 (en) 2018-10-05 2023-04-05 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
MX2022015254A (es) 2023-01-11
WO2021245186A1 (en) 2021-12-09
CN115698001A (zh) 2023-02-03
AU2021285130A1 (en) 2023-01-19
CA3185654A1 (en) 2021-12-09
EP4161920A1 (en) 2023-04-12
KR20230019198A (ko) 2023-02-07
US20230303547A1 (en) 2023-09-28
JP2023529570A (ja) 2023-07-11
CO2022017112A2 (es) 2022-12-09
IL298710A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
BR112022003527A2 (pt) Cianopirrolidinas substituídas com atividade como inibidores de usp30
BR112022020058A2 (pt) N-cianopirrolidinas com atividade como inibidores de usp30
BR112023020483A2 (pt) Compostos para inibir nlrp3 e usos dos mesmos
UY27921A1 (es) Acidos tienil-hidroxamicos sustituidos y su uso para tratar enfermedades asociadas con la actividad enzimática de la histona desacetilasa
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112012027915A2 (pt) nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo
BR112013000537A2 (pt) composição aquosa contendo bromexina
BRPI0708353A8 (pt) Compostos terapêuticos
MX336191B (es) Derivados de carbamato de hexafluoroisopropilo, su preparacion y su uso en terapeutica.
BR112012019765A2 (pt) composto, e, uso de um composto.
BR112012010786A2 (pt) udo de derivados de benzo-heterociclo para medir e tratar câncer ou para inibir metástase de câncer
BR112018013151A2 (pt) alfa-glicosidase ácida aumentada para o tratamento da doença de pompe
BR112022024794A2 (pt) Hexahidropirrolo[3,4-b]pirrolo-5(1h)-carbonitrilas com atividade como inibidores de usp30 para uso no tratamento de disfunção mitocondrial, câncer e fibrose
BR112021016833A2 (pt) Compostos com atividade indutora de ferroptose e métodos de seu uso
EA202091205A1 (ru) Композиции для терапии гипергликемии и сопутствующих состояний
BR112022019722A2 (pt) N-cianopirrolidinas com atividade como inibidores de usp30
BR112023000909A2 (pt) Composições de alvejamento muscular engenheiradas
MX2012005126A (es) Composiciones y metodos para tratar condiciones dermatologicas.
CL2022002540A1 (es) Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensina
WO2023081830A3 (en) Compositions and treatments with nirogacestat
BR112022020644A2 (pt) Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial
BR112022006125A2 (pt) Composições compreendendo hialuronidase e/ou colagenase e/ou 4-metilumbeliferona (4-mu) e métodos de tratamento usando as mesmas
BR112022013173A2 (pt) Composições e métodos para tratar, melhorar e/ou prevenir doenças ou transtornos causados por ou associados com a deficiência de dnase1 e/ou dnase1l3
UY35695A (es) Composicion para el tratamiento contra el envejecimiento de la piel
BR112023010517A2 (pt) 5'-o-fenilacetil uridina e seu uso terapêutico